Elafibranor and liraglutide improve differentially liver health and metabolism in a mouse model of non-alcoholic steatohepatitis.

Nikolaos PerakakisKonstantinos StefanakisMichael FeighSanne S VeidalChristos S Mantzoros

Published in: Liver international : official journal of the International Association for the Study of the Liver (2021)

Liraglutide and elafibranor robustly but through different pathways improve overall metabolic health and liver status in NAFLD. These data indicate important differences in the respective mechanisms of action and support the notion for their evaluation as combination therapies in the future.

Keyphrases

public health
mouse model
healthcare
mental health
health information
health promotion
human health
big data
liver injury
risk assessment
social media
drug induced
data analysis
artificial intelligence